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ABSTRACT
With the introduction of immunomodulatory drugs, proteasome inhibitors, and anti- 
CD38 monoclonal antibodies, major improvements have been achieved in the treatment of 
multiple myeloma (MM), with a significant impact on the outcome of this disease. Different 
treatment combinations are now in use and other therapies are being developed. Based on an 
extensive review of the recent literature, we propose practical recommendations on myeloma 
management, to be used by hematologists as a reference for daily practice.
KEYWORDS 
Multiple myeloma; upfront 




The landscape of treatment in multiple myeloma (MM) 
is rapidly changing. Based on an extensive review of 
the recent literature, we propose an update of our 
recommendations on myeloma care [1], to be used 
by Belgian hematologists as a reference for daily prac-
tice. Levels of evidence and grades of recommenda-
tions are based on previously published methods [2]. 
We recommend participation in clinical trials to gain 
knowledge in the fast-evolving field of MM treatment.
2. Diagnosis
Recommendation 1 – Diagnosis of MM requires the ful-
fillment of the 2014 IMWG criteria (IV,C).
The diagnosis of MM requires the presence of >10% 
clonal plasma cells (PC) in the bone marrow (BM) or in 
a bone or extramedullary lesion biopsy. The majority of 
patients diagnosed with symptomatic (active) MM pre-
sent with symptoms related to organ damage, referred 
to as the CRAB-SLiM criteria [3] (Table 1).
Recommendation 2 – Investigations to be performed 
at diagnosis are listed in Table 2 (IV,C). Cytogenetic 
analysis should follow the IMWG recommendations 
reported in Table 3 (IV,C) [4,5].
3. Staging
Recommendation 3 – All patients should undergo risk 
stratification using the International staging system (ISS) 
(I,A) and cytogenetics (FISH)(II,B), even if risk-adapted 
therapy is not available at the moment in most cases.
The ISS is based on serum β2-microglobulin, the most 
relevant biological prognostic parameter [6]. The revised 
ISS (R-ISS) includes also serum LDH and bone marrow 
FISH analysis done on sorted PC, since cytogenetics 
remains the most prominent prognostic factor (Table 4) 
[7]. High-risk features encompass t(4;14), del(17p), del(1p) 
and gains (1q) [8–10]. Double-hit MM defined by the 
presence of 2 or more high-risk factors, is also associated 
with a very poor outcome (Walker, Leukemia 2019) [11].
Apart from elevated serum LDH, other factors asso-
ciated with aggressive disease include the presence of 
circulating PC or extramedullary disease (EMD). Patient- 
specific factors include age, comorbidities, functional sta-
tus and frailty, that have been clearly associated with 
survival [12,13]. Geriatric assessments to be performed 
at diagnosis are reported in Appendices 1 and 2. Their 
implication in routine assessment can be cumbersome. 
More simple scores based on age, Charlson comorbidity 
index (CCI) and ECOG performance status (PS) can be 
easily performed, providing the same information [14,15].
4. Goal of therapy
Recommendation 4 – The goal of therapy is to achieve 
the best possible response.
Complete response (CR) is the most important surro-
gate marker of overall survival (OS). However, the true 
value of CR relies in the minimal residual disease (MRD) 
status. MRD negativity is associated with better long- 
term outcome [16–18]. Of note, in the elderly, increased 
progression-free survival (PFS) is a worthwhile objective 
if the quality of life (QoL) is maintained and can delay 
the onset of disease complications.
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5. Indication for therapy
Recommendation 5 – Treatment should be considered in 
all patients with a diagnosis of symptomatic MM as 
defined by the IMWG 2014 criteria (IV,C). Treatment 
choice depends on whether or not the patient is eligible 
for autologous stem cell transplantation (ASCT) based 
on age, PS, and comorbidities.
Recommendation 6 – In asymptomatic MM, treat-
ment can only be recommended in the context of 
a clinical trial. Patients should be monitored for symp-
toms and followed every 3 to 6 months according to their 
risk of progression (IV,C).
Treatment of asymptomatic MM (smoldering MM, SMM) 
is not recommended at the moment, although the upfront 
use of Rd (lenalidomide-dexamethasone) showed 
a prolonged PFS and OS [19,20]. In fact, this trial mainly 
concerned high-risk SMM that should nowadays be reclas-
sified as active MM. However, in a more recent trial, time to 
symptomatic MM was prolonged, particularly in high-risk 
SMM [21].
Other very promising studies aim either to control 
and delay progression with prolonged administration of 
immunomodulatory drugs (IMiDs) or monoclonal anti-
bodies (MoAbs), or to cure the disease using aggressive 
approaches such as carfilzomib-lenalidomide-dexa-
methasone (KRd) induction followed by ASCT [22–24].
The risk of progression of SMM can be evaluated by 
the ’3x20ʹ risk score, that refers to a BM plasmocytosis 
>20%, level of M-protein >20 g/l and serum FLC ratio 
>20, and stratifies patients in low-, intermediate- or 
Table 1. CRAB-SLiM criteria (adapted from Rajkumar, Lancet Oncol 2014) [3].
C Hypercalcemia serum calcium >0.25 mmol/l (>1 mg/dl) higher than upper limit of normal or >2.75 mmol/l (>11 mg/dl)
R Renal 
dysfunction
serum creatinin >177 mmol/l (>2 mg/dl) with no other etiology or creatinine clearance < 40 ml/min
A Anemia hemoglobin value >2 g/dl below the lowest limit of normal or a hemoglobin value <10 g/dl
B Bone lesions one or more osteolytic lesions on skeletal x-rays, WBLDCT or PET-CT. If BM < 10% clonal PC, more than one bone lesion is required 
to distinguish MM from solitary plasmocytoma with minimal BM involvement
S ≥60% clonal BM PC
Li serum FLC ratio involved/uninvolved ≥100
M more than 1 focal lesion (≥5 mm each) detected on MRI studies
Abbreviations: BM, bone marrow; FLC, free light chain; M-protein, monoclonal protein; MM, multiple myeloma; PC, plasma cell; PET, positron emitting 
tomography; MRI, magnetic resonance imaging; WBLDCT, whole-body low-dose computed tomography
Table 2. Investigations required at diagnosis.
Biological tests serum blood count, urea, creatinin, calcium, phosphorus proteins, electrophoresis of serum/urine, quantification of 
immunoglobulins immunofixation on serum/urine, characterization of heavy/light chains M-protein quantification in 
serum/urine (24 h urine concentrate) measurement of FLC in oligo- or non-secretory and light chain MM albumin, beta- 
2-microglobulin CRP, LDH
Bone marrow aspirate bone marrow aspirate and trephine biopsy, flow cytometry 
FISH analysis or another equivalent molecular genetic technique on selected or identified plasma cells
Radiology (at choice) WBLDCT or standard skeletal survey if WBLDCT not available 
x-rays of symptomatic areas 
spine MRI plus x-rays of the skull, humeri, femora and ribs or WBMRI 
PET-CT
Abbreviations: FISH, fluorescence in situ hybridization; FLC, free-light chain; MM, multiple myeloma; MRI, magnetic resonance imaging; PET-CT, positron 
emission tomography computed tomography; WBLDCT, whole-body low-dose computed tomography
Table 3. International myeloma working group consensus panel on interphase FISH (adapted from sonneveld, blood 2016 and 
rack, Leukemia 2019) [4,5].





+ t(11;14), t(14;20), del(1p), del(13q) and ploidy status
Abbreviations: IMWG, International Myeloma Working group.
Table 4. Revised ISS risk stratification for MM (adapted from Palumbo, JCO 2015) [7].
MM Patients
Stage I – standard risk 
20%
Stage II–intermediate risk 
60%
Stage 3 – high risk 
20%
Parameters ISS I 
and standard risk cytogenetics by iFISH 
and normal LDH
Not R-ISS I or III ISS III 
and either 
HR cytogenetics by iFISH 
or elevated LDH
Median PFS 66 months 42 months 29 months
5-y OS 82% 62% 40%
Median OS not reached 83 months 43 months
Abbreviations: iFISH, interphase FISH; ISS, international staging system; HR cytogenetics, high-risk cytogenetics defined by the presence of del(17p) and/or 
t(4;14) and/or t(14;16); MM, multiple myeloma; PFS, progression-free survival; OS, overall survival
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high-risk groups with a median PFS of 110, 68 or 
29 months, respectively [25].
Recommendation 7 – Solitary plasmocytoma should 
be treated with radiation therapy.
Solitary plasmocytoma is usually managed with radia-
tion therapy with 40–50 Gy administered in fractionated 
doses [26]. Careful follow-up is mandatory since two- 
thirds of patients progress to MM at 10 years, particularly 
in case of persistence of M-spike after radiotherapy [27].
6. Treatment of newly diagnosed MM not 
eligible for transplant
Recommendation 8 – Before starting therapy, elderly 
patients should be assessed for risk factors defined as 
age over 75, presence of comorbidities, frailty, or disability.
Frailty, defined as a complex syndrome of physiologic 
decline associated with increased vulnerability, is recog-
nized as an adverse risk factor even more discriminative 
than age or cytogenetics. In this perspective, it is highly 
recommended to perform, in collaboration with geriatric 
specialists, a comprehensive geriatric assessment (GA) that 
can predict both survival and toxicities in elderly MM 
patients.
The complexity of carrying for older patients arises 
in part from the heterogeneity of aging. GA tools have 
been shown to accurately assess the risk of morbidity 
and mortality in cancer patients independent of age 
and PS. In MM, geriatric scales, even complex, are help-
ful to identify frail patients [12,13], predict drug toxi-
cities [28], and adapt therapy [13]. Because their 
implication in routine can be cumbersome, simpler 
scores based on age, the Charlson comorbidity index 
(CCI) and the ECOG PS have been developed, that 
provide similar informations [14,15] (Appendices 3,4).
Recommendation 9 – Outside clinical trials, patients 
not eligible for ASCT should receive either VMP (bortezo-
mib-melphalan-prednisone), Rd or VRd (bortezomib- 
lenalidomide-dexamethasone) as standard front-line 
therapy. Based on the FIRST trial, MPT (melphalan- 
thalidomide-dexamethasone) is no more considered as 
a standard of care.
There is no evidence of the superiority of VMP over 
Rd in the absence of randomized clinical trials [29,30]. In 
contrast, compared to Rd, VRd is associated by better 
overall response rates (ORR), PFS and overall survival 
(OS) [31], and has become a new standard of care.
Recommended treatment duration is eight cycles 
for VRd, followed by lenalidomide maintenance, nine 
cycles for VMP, and up to progression for Rd, but can 
be shorter because of therapy-related toxicities.
VRd is effective in all age subgroups, including 
patients over 75, but should be preferred for fit elderly 
patients [31]. VRd lite is a highly effective alternative 
for less fit patients that balances adequately efficacy 
and toxicity [32].
Bortezomib-based regimens may be preferred in 
patients with high-risk cytogenetics, renal impairment 
and increased risk for VTE or contra-indications to 
anticoagulants, but requires antiviral prophylaxis 
against herpes zoster and monitoring for drug-related 
polyneuropathy (PN). This neurotoxicity can be 
reduced by weekly dosing as well as by subcutaneous 
administration, without impact on OS [33,34]. Rd may 
be preferred in patients with pre-existing PN, but 
requires prophylactic anticoagulation and dose reduc-
tion in case of renal dysfunction. It is better tolerated 
when given with low-dose dexamethasone (20 mg per 
week in patients over 75) [35,36]. Dexamethasone can 
even be stopped after nine cycles in intermediate-fit 
patients, without any impact on ORR, PFS, or OS [37].
Regarding the VMP regimen, there is no advantage 
to replace bortezomib by carfilzomib (KMP) [38]. In 
contrast, melphalan can be replaced by cyclophospha-
mide (VCD) with high response rates, prolonged PFS, 
and good tolerability [39].
The combination of daratumumab to VMP (Dara- 
VMP, ALCYONE trial) provides very high ORR and 
a 50% reduction of the risk of progression/death, 
a benefit consistent across all subgroups including 
patients over 75, ISS 3, renal impairment and high- 
risk cytogenetics [40], without additional toxicities 
except for increased infectious events. It is also asso-
ciated with OS prolongation [41]. In unfit elderly MM 
patients, other combinations such as Dara-Ixazomib- 
dexamethasone (Dara-Ixa-d) are under investigation 
with the purpose to limit toxicity [42].
The Rd regimen serves as backbone for triplet combi-
nations with proteasome-inhibitors (PI) or other agents. 
The addition of daratumumab to Rd (Dara-Rd, MAIA trial) 
results in a 93% ORR, nearly doubling the ≥CR rate com-
pared to Rd, and inducing a threefold higher MRD nega-
tivity (24% vs. 7%) that translates in a 44% reduction of 
the risk of progression/death, at the cost of more grade 
3–4 neutropenia and pneumonia [43].
Other combinations using PI (KRd, Ixa-Rd) or MoAbs 
(Dara-VRD, isatuximab-VRD (IMROZ), sqDara-VRD 
(CEPHEUS), elotuzumab-Rd) are also under investiga-
tion. Preliminary results fail to demonstrate any super-
iority of elotuzumab or ixazomib combined with Rd, 
compared to Rd (unpublished data).
Common induction regimens used in transplant- 
ineligible patients are listed in Table 5.
Recommendation 10 – Continuous therapy with Rd is 
recommended until progression.
Continuous Rd is associated with an improvement in 
PFS when compared to Rd given for a fixed duration of 
18 months, a benefit even more prominent in patients 
achieving at least very good partial response (VGPR) 
[44], at the cost of more toxicities, particularly in the 
very old and frail population [30]. Duration of therapy 
should take into account patient preferences, toxicities, 
QoL and costs.
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Future studies will evaluate the role of less toxic 
agents such as MoAbs as well as the role of MRD 
testing for selecting patients that are more susceptible 
to benefit from continuous therapy.
7. Treatment of newly diagnosed MM eligible 
for transplant
Recommendation 11 – In transplant-eligible MM, induction 
followed by high-dose melphalan (HDM) and ASCT remains 
the standard of care in patients in good clinical condition. 
Based on response rates, depth of response, and PFS, 3-drug 
induction including at least bortezomib and dexametha-
sone is considered the standard of care before ASCT (I,A).
VTD (bortezomib-thalidomide-dexamethasone) is 
superior to VCD but at the cost of more peripheral 
polyneuropathies [45]. Substitution of thalidomide by 
lenalidomide (VRD) results in significantly higher 
response rates, response duration and PFS [31,46,47] 
compared to previous studies using VTD. There is no 
phase 3 trial comparing head-to-head VTD and VRD. 
Replacement of bortezomib by carfilzomib (KRD) is 
highly effective with up to 89% ORR, particularly regard-
ing the achievement of MRD negativity (up to 58%) [48].
Similarly, addition of daratumumab to VTD (Dara- 
VTD, CASSIOPEIA trial) significantly improves the rates 
of stringent complete response (sCR), MRD negativity, 
and 18-month PFS [49]. Similar results are awaited with 
the dara-VRD (GRIFFIN trial) [50] or dara-KRD combi-
nations [51].
VRD, carfilzomib, and daratumumab are not reim-
bursed in first-line therapy in Belgium.
Current induction regimens are listed in Table 6.
Recommendation 12 – Four cycles are recommended 
before stem cell collection (SCC). There is no data identifying 
the ideal depth of responses required prior to proceed to 
ASCT.
Since post-transplant depth of response is more 
important than pre-transplant response, ASCT should 
be performed independently of depth of response, 
except in patients with progressive disease [52].
Recommendation 13 – Sufficient SCC (at least for 
more than one ASCT) should be considered upfront, 
since later SCC can be hampered after prolonged drug 
exposure such as melphalan or IMiDs.
Successful engraftment can be achieved with 2 × 106 
CD34+ peripheral hematopoietic stem cells/kg, but the 
optimal target is usually 5 × 106 CD34+/kg per transplant.
Mobilization is achieved using filgrastim (10 μg/kg/ 
day for 4–6 consecutive days, apheresis on days 5–6) or 
cyclophosphamide (2–4 g/m2).
Prolonged exposure to lenalidomide may impair 
SCC. In this case, apheresis should not be performed 
beyond 4 cycles and may require the use of cyclopho-
sphamide or plerixafor [53].
Recommendation 14 – Conditioning with melphalan 
200 mg/m2 (MEL200) remains the standard regimen used 
prior to ASCT.
Dose reductions (140 mg/m2) are recommended in 
case of renal impairment (estimated GFR <60 ml/min) 
[54]. There is no benefit to add total body irradiation 
(TBI) or any other agent such as bortezomib [55].
Recommendation 15 – Upfront ASCT remains the cor-
nerstone in the management of newly diagnosed (ND)MM, 
since it increases response rates, depth of response, MRD 
negativity and PFS, when used after a triplet induction.
In the IFM 2009 trial, VRD induction plus ASCT 
opposed to VRD alone results in significant improvement 
in PFS (50 vs. 36 months, HR 0.65), CR rate (59% vs. 48%), 
MRD negati 
vity (79% vs. 65%) and median time to progression (mTTP) 
(50 vs. 36 months), but with no effect on OS, taking into 
account that transplantation could not be done in one- 
third of the patients due to age, comorbidities, or progres-
sion [46].
In the EMN02-HO95 trial, upfront ASCT (single or dou-
ble) compared to VMP after VCD induction was associated 
with a decreased risk of progression/death and improved 
3-year PFS, regardless of initial adverse prognostic fac-
tors [56].
The role of upfront ASCT is further challenged by 
the addition of MoAbs such as daratumumab to triplet 
induction regimens [49,50], or the use of second- 
generation PI such as carfilzomib [48,51]. It is likely 
that the MRD status achieved after induction will 
have an impact on ASCT decisions in the future.
Recommendation 16 – Tandem ASCT can be bene-
ficial for patients with high-risk cytogenetic features or 
those with a suboptimal response to first transplant.
In the EMN02/HO95 trial, tandem ASCT improved 
the depth of response by 25%, with more than 50% 
patients achieving at least CR. It was also associated 
with an advantage over single transplant in terms of 
PFS and OS, particularly in high-risk disease (3-year 
PFS, 69% vs. 44%). Double transplant emerged as an 
independent prognostic factor predicting PFS [56].
On the opposite, tandem ASCT failed to show any 
PFS or OS advantage over single transplant in the 
StaMINA trial, in the context of lenalidomide mainte-
nance. Of note, this study had several limitations such 
as various induction regimens including doublets, 
given for various durations, and more than 30% of 
patients randomized to tandem ASCT did not receive 
the second transplant [57].
Recommendation 17 – The role of consolidation is still 
unclear. The optimal regimen, number of cycles and sub-
groups that will benefit from consolidation as well as its 
efficacy when followed by optimal maintenance in the era 
of novel agents are questions that should be answered. It 
remains a reasonable practice in patients who failed to 
achieve at least CR after transplantation.
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Bortezomib-based consolidation is associated with 
increased CR, molecular CR, and prolonged PFS in 
patients achieving a good response after transplanta-
tion, but has no impact on OS [58,59].
More recently, two trials evaluated the role of VRD in 
consolidation after ASCT. In the EMN02-HO95 trial, two 
cycles of VRD were superior to no consolidation, except 
in high-risk diseases [56]. On the opposite, the StaMINA 
trial failed to identify any PFS benefit using either 
a second transplant or three cycles of VRD consolidation 
[57]. Both studies were different in terms of design, and 
the lack of PFS benefit may be influenced by the follow- 
up as well as the maintenance given to all patients. 
Attempts to guide consolidation decisions based on 
the MRD status obtained after ASCT are ongoing [51].
Recommendation 18 – Maintenance with lenalido-
mide after ASCT is considered a standard of care since it 
improves OS. In addition, it can favor the conversion to 
MRD negativity. Its benefit in high-risk diseases is less 
clear, and the optimal duration of maintenance is still 
a matter of debate. Overall, an average duration of 
2 years with a 3-week on, 1-week off treatment has 
become widely adopted. It exposes patients to an 
increase incidence, albeit modest, of second primary 
malignancies (SMP).
Daily lenalidomide given in monotherapy at the 
dosage of 10–15 mg significantly improves PFS, 
regardless of age, disease stage, induction regimen 
(exposure to lenalidomide in induction) and depth of 
response after transplant. It also significantly improved 
OS, with a 25% reduction in the risk of death, increas-
ing the median OS by approximately 2.5 years, except 
in high-risk diseases where conflicting data have been 
published [60,61].
The OS benefit of lenalidomide maintenance largely 
outweights the risk of developing an SPM [60]. Patients 
should be informed and monitored accordingly.
Recommendation 19 – Maintenance with bortezo-
mib should be preferred in high-risk patients, but is not 
approved by EMA or national health systems.
Bortezomib given every other week for 2 years 
after a tandem ASCT was the first to demonstrate 
a survival advantage compared to thalidomide, parti-
cularly when used in induction, in patients with del 
(17p) [62]. Ixazomib, an oral PI given once weekly for 
2 years, improves PFS by 39% and reduces the risk of 
progression/death by 28%, when compared to placebo 
[63], but is not approved in this indication. Additional 
trials incorporating pomalidomide, carfilzomib, and 
MoAbs are currently ongoing.
Selected maintenance regimens used in this setting 
are listed in Table 7.
Recommendation 20 – Consolidation with allogeneic 
transplantation is still considered investigational for 
MM. Because of the risk of severe treatment-related mor-
tality and graft-versus-host disease, it should only be 
performed in young patients with (ultra)-high-risk 
disease in good response [64], preferably within clinical 
trials if available (IV,C).
8. Relapse, definition and indication of 
retreatment
Recommendation 21 – Diagnosis of progression or 
relapse requires the fulfillment of the 2014 IMWG criteria 
(IV,C).
Progressive disease is defined by an increase of at least 
25% in the serum M-protein (with a minimum value of 
0.5 g/dl), or ≥200 mg in light-chain excretion in a 24-h 
urine collection, or an increase ≥100 mg/l in the difference 
of involved/uninvolved light chain in a patient without 
a measurable serum or urine M-protein [65].
Work-up should at least include imaging in order to 
identify new lytic lesions or EMD. BM evaluation is not 
mandatory, but should be performed in case of oligo- 
or non-secretory MM or unexplained cytopenias. 
Cytogenetics by FISH allows to identify abnormalities 
seen at progression such as del(17p) and 1q amplifica-
tion, that predict a more aggressive disease [66]. 
Identification of t(11;14) might be of interest since 
this abnormality has been reported to be sensitive to 
venetoclax.
Recommendation 22 – Biochemical (asymptomatic) 
relapses that require close observation should be differ-
entiate from clinical (symptomatic, with CRAB features) 
relapses that require immediate treatment.
9. Early relapses
Recommendation 23 – Treatment choice at relapse will be 
based on various factors including the timing and aggres-
siveness of relapse, response, and tolerance to prior thera-
pies, age, and PS, drug availability, and patients preferences. 
Participating in clinical trials should always be proposed.
Recommendation 24 – Salvage ASCT should be con-
sidered in patients who never had one as part of their 
front-line therapy and in those who enjoyed a prolonged 
remission after a first ASCT.
This refers to a remission of at least 36 months when 
maintenance was part of initial therapy [67]. It is, how-
ever, important to balance the risk, albeit modest, and 
side effects of ASCT with the excellent PFS obtained so 
far with new combinations.
Recommendation 25 – Recommended strategy ideally 
requires a switch of drugs regarding those used in front- 
line, from PI-based to IMiD-based regimens, or vice-versa. 
Triplet combinations appear to be superior to doublets, 
in terms of prolonging PFS. Doublets are not recom-
mended for high-risk diseases.
The best triplet and sequence of administration 
remains unclear in this setting, since there have been 
no head-to-head trials comparing the newer agents. 
Dara-Rd provides the longest PFS, with a higher rate of 
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CR and MRD negativity [68], while KRd is associated 
with an OS benefit [69].
Triplets administration should be recommended in 
fit and/or high-risk patients, and should be continued 
until progression. There are not enough data to recom-
mend to stop therapy based on response such as 
achievement of a negative MRD status.
Common regimens used in first relapses are 
reported in Table 8.
Recommendation 26 – With lenalidomide increasingly 
used in the frontline setting and for longer periods of time, 
patients refractory to lenalidomide represent an unmet 
need population with significantly lower median PFS.
Resistance to lenalidomide is not dose-dependent. 
Patients with a longer duration of prior lenalidomide 
therapy (>12 months)(possible inherent IMiD sensitiv-
ity), and longer IMiD-free interval (≥18 months)(poten-
tial re-emergence of IMID-sensitive clones), have longer 
PFS and OS, irrespective of prior lines of therapy [70].
In this context, PVd (pomalidomide-bortezomib- 
dexamethasone) offers a significant PFS benefit in 
patients already exposed (100%)/refractory (70%) to 
lenalidomide (Table 8). The benefit is even more impor-
tant in patients exposed to only one prior line of therapy 
[71]. Similarly, KPd (carfilzomib-pomalidomide-dexame 
thasone) is effective in patients already exposed/refrac-
tory to bortezomib and lenalidomide [72]. Final results 
from trials combining Kd or Pd with anti-CD38 or anti- 
SLAMF7 MoAbs are eagerly awaited.
Pomalidomide is reimbursed after two lines of ther-
apy, PVd has been be reimbursed as from 1 May 2020. 
KPd or other combinations are not reimbursed at the 
moment.
10. Later relapses
Recommendation 27 – In later relapse, there is no standard 
of care. Benefits and potential risks should be balanced to 
minimize excess toxicities. Enrolling patients in clinical trials 
remain of first importance, if available. The main therapeu-
tic options rely on pomalidomide and daratumumab.
Pomalidomide given in association with dexa-
methasone provides only a 30% ORR, with a 4-month 
mPFS and 12-month mOS [73]. Outcomes are signifi-
cantly improved when pomalidomide is combined 
with cyclophosphamide [74], bortezomib [71], elotuzu-
mab [75], or isatuximab [76], and other associations 
(Dara-Pd, KPd, Ixa-Pd) are being investigated with very 
promising results [77].
Daratumumab monotherapy induces rapid, deep, 
and durable responses, with a clinical benefit that 
extends to patients with stable disease or better [78]. 
Combination with Kd is also effective, including for 
lenalidomide exposed/refractory patients, with a 37% 
reduction in the risk of progression/death [79].
Main trials reported in later relapses are listed in 
Table 9.
Recommendation 28 – In triple-class refractory MM 
patients, prognostic is poor. Inclusion in clinical trials 
should be proposed, in order to provide access to new 
drugs or immunotherapies.
In penta-refractory patients, mOS is less than 
6 months [80]. When progressing under a CD-38 
MoAb-based regimen, prognosis is unfavorable even 
if patients they might still be responsive to a PI or an 
IMiD, opening the way to other combinations.
Conventional chemotherapy can elicit partial but 
transient response in around 50% patients, but is bet-
ter proposed as a bridge to another therapy.
Venetoclax is a selective oral BCL-2 inhibitor, is 
particularly active in association with bortezomib and 
dexamethasone, with an ORR over 90% in patients 
bearing translocations t(11;14) and not refractory to 
bortezomib [81]. There are concerns about infections 
related to the drug [82].
Selinexor is a selective inhibitor of nuclear export 
protein, is also particularly efficient in penta-refractory 
MM patients or in combination with a PI like bortezomib, 
Table 7. Selected maintenance regimens used after ASCT.
Maintenance Schedule mPFS OS
Lenalidomide 
McCarthy, JCO 2017 
[60]
Lenalidomide 10 mg, days 1–21 until progression 52.8 vs. 23.5 m 
HR 0.48
mOS, NR vs. 86 m 
after mFU of 79.5 m 
HR 0.75
MM XI 
R maintenance vs. placebo 
Jackson, Lancet Oncol 2019 
[61]
Lenalidomide 10 mg, days 1–21/28 
until progression
39 vs. 20 m 
after mFU of 31 m 
HR 0.46
3y-OS, 78.6% vs. 75.8% 
HR 0.87
HOVON 
T after VAD-ASCT vs. V after PAD-ASCT 
Sonneveld, JCO 2012 
[62]
Thalidomide 50 mg/d or 
Bortezomib 1.3 mg/m2 qw, for 2 years
28 vs. 35 m 
CR/nCR, 34% vs. 49%
5y-OS, 55% vs. 61%
TOURMALINE-MM3 
Ixazomib vs. placebo 
Dimopoulos, Lancet 2019 
[63]
Ixazomib 4 mg, days 1,8,15 
28-day cycles, for 2 years
26.5 vs. 21.3 m 
after mFU of 31 m 
HR 0.72
Abbreviations: ASCT, autologous stem cell transplantation; CR, complete response; d, day; HR, hazard ratio; m, months; mFU, median follow-up; mPFS, 
median progression-free survival; NA, not available; nCR, near complete response; NR, not reached; OS, overall survival; PAD, bortezomib, adriamycin, 
dexamethasone; PFS, progression-free survival; R, lenalidomide; T, thalidomide; V, bortezomib; VAD, vincristine-adriamycin-dexamethasone.
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with a 84% ORR in PI-non refractory and 43% in PI- 
refractory patients [83]. Results are more modest in com-
bination with dexamethasone, with a 26% ORR, an mDOR 
of 4 months and an mPFS of 3.4 months [84]. Selinexor is 
now studied in combination with various drugs including 
IMiDs, PIs, and MoAbs in the STOMP protocols.
Melflufen is a lipophilic peptide-conjugated alkyla-
tor, a promising new compound with selective cyto-
toxicity to MM cells and strong anti-angiogenic 
properties, able to overcome drug resistance. Tested 
in refractory late-stage MM, it exhibits encouraging 
results with 32% ORR and manageable toxicities [85], 
particularly in association with IMiDs or PI [86].
Iberdomide is a potent cereblon-E3-ligase modula-
tor with anti-tumor and immunostimulatory activities 
in IMiD-refractory MM [87] with favorable efficacy in 
heavily pre-treated patients when given with dexa-
methasone [88].
Immunotherapy with B cell maturation antigen 
(BCMA) as a target opens a new therapeutic era, 
where antibody-drug conjugates [89,90], T-cell bispe-
cific engagers (BiTEs) [91], and CAR T cells [92–95] are 
investigated with promising results.
11. Plasma cell leukemia and extramedullary 
disease
Recommendation 29 – Diagnosis of plasma cell leukemia 
(PCL) requires the fulfillment of the 2013 IMWG criteria 
[96]. Initial work-up should include peripheral blood 
analysis for detecting circulating PC, and PET-CT for 
identifying EMD.
PCL is clinically, biologically, and cytogenetically dis-
tinct from MM, with a younger age at diagnosis, an 
aggressive clinical presentation with a higher association 
to EMD. Of note, MM patients carry the same adverse 
prognosis as PCL in the presence of >5% circulating PC 
[97]. PCL is frequently associated with complex karyo-
types and hypodiploïdy, as well as t(11;14), add(1q) and 
del(17p) [95]. Survival is affected by factors that include 
age <60, platelets count <100,000/μl, PC >20,000/μl [98].
Recommendation 30 – There are no precise guidelines 
in the PCL setting. Clinical trials should always be recom-
mended, if available.
Recommendation 31 – In transplant eligible patients, 
upfront therapy should include a 3-drug bortezomib-based 
regimen or a schema used in aggressive lymphomas, fol-
lowed by HDM and ASCT, consolidation with 2–4 bortezo-
mib-based cycles or second ASCT, and maintenance with 
bortezomib until progression (IB). Consolidation with allo- 
SCT can be considered in young patients (IB), in the setting of 
a clinical trial, if available.
Upfront therapy should include a triplet regimen with 
at least a PI and an IMiD (VTD/VRd, KRd, or PAD). The IFM 
proposed to alternate PAD and VCD for four cycles [99]. In 
patients with high disease burden or non-responsive to 
initial therapy, VTD/VRD-PACE or hyperCVAD-VD should 
be considered, since doxorubicin and cyclophosphamide 
are particularly active in lymphoproliferative diseases. 
ASCT upfront, in tandem if possible, is recommended to 
achieve a deeper response and longer disease control. 
Consolidation should be proposed in patients not achiev-
ing CR, followed by maintenance with either bortezomib 
or lenalidomide [100,101]. Allo-SCT should only be con-
sidered on a case-to-case basis. Attention has been drawn 
to venetoclax that induces deep responses in refractory 
primary PCL with t(11;14) [102].
Recommendation 32 – In transplant ineligible 
patients, treatment should be based on bortezomib 
(VMP or VRD regimens) followed by maintenance.
In elderly or frail patients, induction with VCD or 
VRD can be used as a milder alternative, given for up to 
8–10 cycles, followed by indefinite maintenance ther-
apy to keep the disease under control [101].
Recommendation 33 – Extramedullary disease is consid-
ered as high-risk disease and should be treated accordingly.
EMD is defined by the presence of PC outside the 
BM. It can be found in up to 30% of MM patients across 
the overall disease course, and is associated with 
adverse prognostic factors and poor prognosis. 
Spread to soft tissues is associated with worse out-
comes compared to involvement of bones [103].
12. Response assessment
Recommendation 34 – Responses to therapy should 
be assessed using the IMWG response criteria.
Response assessment includes evaluation of the 
level of M-protein by serum and urine protein electro-
phoresis every month while on therapy, and every 
3–4 months when off-therapy. The FLC assay is needed 
to monitor patients who lack a measurable M-protein, 
particularly in oligo- or non-secretory and light-chain 
MM, provided the FLC ratio is abnormal and the 
involved FLC level is ≥100 mg/l. It is also required to 
define the stringent CR criteria [65].
MRD negativity has been associated with improved 
outcomes [16–18]. It is defined as the absence of detect-
able disease either by next-generation sequencing (NGS) or 
next generation flow (NGF) [65] and imaging (Pet-CT) [104]. 
It is now regularly assessed in clinical trials and represents 
the future treatment goal in MM [104]. Efforts are made to 
determine the optimal timing, frequency and level of sen-
sitivity of MRD testing, as well as its impact on treatment 
decisions. However, at the moment, it is not used routinely.
13. Supportive care
Recommendation 35 – Supportive care should follow 
international guidelines.
Recommendation 36 – Renal failure requires prompt 
rehydration and treatment of precipitating events (IV,C). 
High-dose dexamethasone should be started immedi-
ately (IV,C). Bortezomib is safely used without dose 
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modification, even in patients under dialysis (IV,C). Triplet 
combinations such as VCD or VTD should be preferred 
(IV,C). Lenalidomide requires appropriate dose reductions 
(IV,C). The place of physical methods to remove FLC from 
the blood is still controversial. ASCT can be proposed for 
patients with GFR <30 ml/min, including patients on 
dialysis, using melphalan 100–140 mg/m2 (II,B).
Recommendation 37 – Bone disease concerns up to 
80% of MM patients, and should be treated with bipho-
sphonates in all symptomatic MM regardless the presence of 
lytic lesions. Because of the risk of osteonecrosis of the jaw 
(ONJ), dental evaluation should be carried out before start-
ing therapy.
Both zoledronic acid (ZA) and pamidronate are 
effective with respect to skeletal-related events (SRE) 
prevention, but ZA has been associated with 
a prolonged OS [105]. Dose should be adjusted in 
patients with moderate renal dysfunction (creatinine 
clearance 30–60 ml/min) [106]. Denosumab is an anti-
body targeting RANK ligand that has the advantage of 
being administered subcutaneously while not being 
cleared by the kidneys. Compared to ZA, denosumab 
provides a lower rate of SRE and a prolonged PFS, but 
without OS benefit [107].
There is no consensus regarding the duration of 
bisphosphonate therapy. However, given the risk of 
ONJ, it should not be administered longer than 
2 years [106,108]. Dental evaluation should be carried 
out before starting therapy and invasive dental proce-
dures should be avoided thereafter.
Recommendation 38 – MM patients have an increased 
risk of thromboembolic event, a risk that is significantly 
enhanced by the use of specific therapeutic agents. Risk of 
thrombosis should be assessed before starting therapy.
Apart from personal risk factors (age, obesity, inher-
ited thrombophilia, familial history of thrombosis, sur-
gery, immobilization, presence of catheter), MM 
patients presented an increased risk of thrombosis 
that is significantly enhanced by the use of high-dose 
dexamethasone, anthracyclines, growth factors (EPO), 
IMiDs and carfilzomib [109].
Patients due to initiate an IMiD-based therapy 
should be started on aspirine 100 mg daily in the 
absence of risk factors, or low-molecular-weight- 
heparin (LMWH) in higher risk situations, for at 
least 4–6 months or as long as the risk of thrombo-
sis remains high [106]. LMWH requires dos 
age adaptation in patients with renal impairment. 
New oral anticoagulants (NOAC) are effective, safe, 
and patient-friendly [110,111]. Thalidomide or lena-
lidomide monotherapy does not require 
thromboprophylaxis.
Recommendation 39 – MM patients have an 
increased risk of infectious complications, particularly 
at start of therapy when the disease is active, in elderly 
frail patients.
Infections represent the second cause of mortality 
in MM patients. Performance status, serum β2-micro 
globulin, LDH, and hemoglobin levels have been 
recognized as prognostic factors of the occurrence of 
≥ grade 3 infections [112].
Antibiotic prophylaxis remains controversial, but 
may be beneficial within the first 2–3 months in 
patients under lenalidomide or pomalidomide, or 
in those at high-risk (previous severe infections, 
neutropenia) [106,113]. Prophylactic acyclovir/ 
valacyclovir is recommended in patients receiving 
PI or MoAbs, as well as vaccination against strep-
tococcus pneumonia and influenza [106]. 
Prophylactic immunoglobulins are not routinely 
recommended, except in patients with severe, 
recurrent bacterial infections [106].
Recommendation 40 – Due to older age, comorbidities, 
and use of immunosuppressive therapies, MM patients 
might be at higher risk of severe COVID-19.
SARS-CoV2 is a novel coronavirus responsible for 
a pandemic disease called COVID-19. Transmission 
mainly occurs through contact with respiratory dro-
plets from infected patients. Symptoms, usually occur-
ring around 2 to 14 days after viral exposure, are non- 
specific, including fever, cough, chest pain, shortness 
of breath, conjun 
ctivitis, anosmia and ageusia, less frequently, nausea, 
and diarrhea. Treatment is mainly supportive [114].
International propositions are summarized in 
Table 10.
Table 10. International propositions regarding the COVID-19 pandemic.
1 Advice patients of their vulnerability to COVID-19 with regards to the weakness of their immune system
2 Consider oral regimens rather treatments that require IV/sq administration 
deliver oral treatment for 2 months at a time
3 Reduce the dosage of dexamethasone to 20 mg weekly, or to 10 mg weekly in patients >70, 
consider stopping it in some cases
4 Consider using a reduced frequency of IV drugs in patients harbouring an excellent response (i.e. weekly carfilzomib, monthly daratumumab – 
starting cycle 3)
5 For patients starting VRD in the non-transplant setting, consider to initiate therapy with Rd, and adding bortezomib later on; in high-risk diseases, 
consider home sq administration 
For patients on VRD, consider to change to Rd if appropriate, or, if high-risk, continue with bortezomib home sq administration
6 For patients eligible for ASCT, postpone stem cell collection and front-line ASCT by adding 2 additional cycles of induction 
In patients with active/high-risk disease, do not postpone therapy
7 In patients with immunoparesis associated with severe infections, continue immunoglobulins infusions; consider home sq administration
8 In regards to clinical trials, avoid including new patients 
In patients already participating in a studied, use telemedicine for follow-up, in order to avoid unnecessary visits to the hospital
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14. Conclusions
The treatment landscape of MM is rapidly evolving. 
Changes in the front-line setting will inevitably impact 
treatments proposed at relapse (Table 11). Long-term 
therapy with Rd at diagnosis and introduction of 
MoAbs up-front will also undoubtedly influence the 
therapeutic efficacy of Rd-based triplets proposed at 
relapse [115].
Acknowledgments
MCV wrote the manuscript.
All authors critically reviewed the manuscript and 
approved the final version.
Disclosure statement
The authors have no conflict of interest to declare.
The authors declared no funding sources in the study design, 
collection of the data, in the writing of the manuscript and in 
the decision to submit the manuscript for publication.
References
[1] Vekemans MC, Beel K, Caers J, et al. Update on the 
initial therapy of multiple myeloma. Belg J Hematol. 
2014;5(4):126–137.
[2] Smith A, Wisloff F, Samson D. Guidelines on the diag-
nosis and management of multiple myeloma. Br 
J Haematol. 2006;132(4):410–451.
[3] Rajkumar SV, Dimopoulos MA, Palumbo A, et al. 
International myeloma working group updated cri-
teria for the diagnosis of multiple myeloma. Lancet 
Oncol. 2014;15(12):e538–48.
[4] Sonneveld P, Avet-Loiseau H, Lonial S, et al. Treatment 
of multiple myeloma with high-risk cytogenetics: 
a consensus of the international myeloma working 
group. Blood. 2016;127(24):2955–2962.
[5] Rack KA, van den Berg E, Haferlach C, et al. European 
recommendations and quality of assurance for cyto-
genomic analysis of haematological neoplasms. 
Leukemia. 2019;33(8):1851–1867.
[6] Greipp PR, San Miguel JF, Durie BG, et al. International 
staging system for multiple myeloma. J Clin Oncol. 
2005;23(15):3412–3420.
[7] Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised 
international staging system for multiple myeloma: 
a report from international myeloma working group. 
J Clin Oncol. 2015;33(26):2863–2869.
[8] Avet-Loiseau H, Attal M, Campion L, et al. Long-term 
analysis of the IFM 99 trials for myeloma: cytogenetic 
abnormalities [t(4;14), del(17p), 1q gains] play a major 
role in defining long-term survival. J Clin Oncol. 
2012;30(16):1949–1952.
[9] Hebraud B, Leleu X, Lauwers-Cances V, et al. Deletion 
of the 1p32 region is a major independent prognostic 
factor in young patients with myeloma: the IFM experi-
ence on 1195 patients. Leukemia. 2014;28(3):675–679.
[10] Perrot A, Corre J, Avet-Loiseau H. Risk stratification and 
targets in multiple myeloma: from genomics to the 
bedside. American Society of Clinical Oncology 
Educational Book 2018; 38(38):675–680.
[11] Walker BA, Mavrommatis K, Wardell CP, et al. A 
high-risk, double-hit, group of newly-diagnosed mye-
loma identified by genomic analysis. Leukemia. 
2019;33(1):159–170.
[12] Larocca A, Bringhen S, Evangelista A, et al. A simple 
score, based on geriatric assessment, improves predic-
tion of survival, and risk of serious adverse events in 
elderly newly diagnosed multiple myeloma patients. 
Blood. 2013;122(21):687.
[13] Palumbo A, Bringhen S, Mateos MV, et al. Geriatric 
assessment predicts survival and toxicities in elderly 
myeloma patients: an international myeloma working 
group report. Blood. 2015;125(13):2068–2074.
[14] Facon T, Dimopoulos MA, Meuleman N, et al. 
A simplified frailty score predicts outcomes in trans 
plant-ineligible patients with newly-diagnosed multi-
ple myeloma treated in the FIRST (MM-020) trial. 
Leukemia. 2020;34:224–233.
[15] Stege CAM, van der Holt B, Dinmohamed AG, et al. 
Validation of the FIRST simplified frailty scale using the 
ECOG performance status instead of patient-reported 
activities. Leukemia. 2020; DOI:10.1038/s41375-020- 
0713-4
[16] Lahuerta JJ, Paiva B, Vidriales MB, et al. Depth of 
response in multiple myeloma: a pooled analysis of 
three PETHEMA/GEM clinical trials. J Clin Oncol. 
2017;35(25):2900–2910.
Table 11. Expected landscape of MM in the near future.
First line – transplant eligible MM 
VTD, Dara-VTD 
VCD 
(VRD), Dara-VRD, Isa-VRD 
KRd, Dara-KRd 
maintenance with R





First relapse – bortezomib-based regimens 
Doublets: Vd, Kd 
Triplets: Dara-Vd, Dara-Kd, Isa-Kd 
VCD, Elo-VD, PVd, KPd
First relapse – lenalidomide-based regimens 
Doublets: Rd 
Triplets: Dara-Rd, KRd, Ixa-Rd, Elo-Rd
Second relapse and beyond 
Pomalidomide-based: Pd, PVd, PCd, Elo-Pd, Dara-Pd, Ixa-Pd, KPd, Isa-Pd 
Others: Pano-VD, Sel-D, Sel-Pd, Sel-Vd,Dara-Kd, Isa-Kd 
Dara monotherapy 
Chemotherapy: DTC-PACE, PAD 
Clinical trials 
Immunotherapy: immunoconjugates – CAR-T cell therapy – BiTEs 
Others: venetoclax – melflufen – CELMoD
ACTA CLINICA BELGICA 13
[17] Paiva B, Puig N, Cedena MT, et al. Measurable residual 
disease by next-generation flow cytometry in multiple 
myeloma. J Clin Oncol. 2020;38(8):784–792.
[18] Perrot A, Lauwers-Cances V, Corre J, et al. Minimal 
residual disease negativity using deep sequencing is 
a major prognostic factor in multiple myeloma. Blood. 
2018;132(23):2456–2464.
[19] Mateos MV, Hernández MT, Giraldo P, et al. Lenalidomide 
plus dexamethasone for high-risk smoldering multiple 
myeloma. N Engl J Med. 2013;369(5):438–447.
[20] Mateos MV, Hernández MT, Giraldo P, et al. 
Lenalidomide plus dexamethasone versus observation 
in patients with high-risk smouldering multiple mye-
loma (quiredex): long-term follow-up of a randomised, 
controlled, phase 3 trial. Lancet Oncol. 2016;17 
(8):1127–1136.
[21] Lonial S, Jacobus S, Fonseca R, et al. Randomized trial 
of lenalidomide versus observation in smoldering mul-
tiple myeloma. J Clin Oncol. 2020;38(11):1126–1137.
[22] Mateos MV, Martinez-Lopez J, Rodriguez-Otero P, et al. 
Curative strategy (GEM-CESAR) for high-risk smolder-
ing myeloma (SMM): carfizomib, lenalidomide and 
dexamethasone (KRd) as induction followed by 
HDT-ASCT, consolidation with KRd and maintenance 
with Rd. Blood. 2019;134(suppl 1):781.
[23] Mateos MV, Gonzalez-Calle V. Timing of treatment of 
smoldering myeloma: early treatment. Blood Adv. 
2018;2(21):3045–3049.
[24] Landgren O, Chari A, Cohen YC, et al. Daratumumab 
monotherapy for patients with intermediate or 
high-risk smoldering multiple myeloma: a randomized, 
open-label, multicenter phase 2 study (centaurus). 
Leukemia. 2020; DOI:10.1038/s41375-020-0718z
[25] Lakshman A, Rajkumar SV, Buadi FK, et al. Risk stratifi-
cation of smoldering multiple myeloma incorporating 
revised IMWG diagnostic criteria. Blood Cancer J. 
2018;8(6):59.
[26] Caers J, Paiva B, Zamagni E, et al. Diagnosis, treatment, 
and response assessment in solitary plasmacytoma: 
updated recommendations from a European expert 
panel. J Hematol Oncol. 2018;11(1):10.
[27] Reed V, Shah J, Medeiros LJ, et al. Solitary plasmacyto-
mas: outcome and prognostic factors after definitive 
radiation therapy. Cancer. 2011;117(19):4468–4474.
[28] Engelhardt M, Dold MS, Ihorst G, et al. Geriatric assess-
ment in multiple myeloma patients: validation of the 
international myeloma working group (IMWG) score 
and comparison with other common comorbidity 
scores. Haematologica. 2016;101(9):1110–1119.
[29] San Miguel JF, Schlag R, Khuageva NK, et al. 
Bortezomib plus melphalan and prednisone for initial 
treatment of multiple myeloma. N Engl J Med. 2008; 
359(9):906–917.
[30] Benboubker L, Dimopoulos MA, Dispenzieri A, et al. 
Lenalidomide and dexamethasone in transplant-ineligi 
ble patients with myeloma. N Engl J Med. 2014;317 
(10):906–917.
[31] Durie BG, Hoering A, Abidi MH, et al. Bortezomib with 
lenalidomide and dexamethasone versus lenalido-
mide and dexamethasone alone in patients with 
newly diagnosed myeloma without intent for immedi-
ate autologous stem-cell transplant (SWOG S0777): 
a randomised, open-label, phase 3 trial. Lancet. 
2017;389(10068):519–527.
[32] O’Donnell EK, Laubach JP, Yee AJ, et al. A phase 2 
study of modified lenalidomide, bortezomib and 
dexamethasone in transplant-ineligible multiple 
myeloma 
Br J Haematol. 2018;182(2):222–230.
[33] Mateos MV, Oriol A, Martinez-Lopez J, et al. Bortezomib, 
melphalan, and prednisone versus bortezomib, thalido-
mide, and prednisone as induction therapy followed by 
maintenance treatment with borte zomib and thalido-
mide versus bortezomib and prednisone in elderly 
patients with untreated multiple myeloma: 
a randomized trial. Lancet Oncol. 2010;11(10):934–941.
[34] Moreau P, Polypenko H, Grosicki S, et al. Subcutaneous 
versus intravenous administration of bortezomib in 
patients with relapsed multiple myeloma: 
a randomized, phase 3, non-inferiority study. Lancet 
Oncol. 2011;12(5):431–440.
[35] Rajkumar SV, Jacobus S, Callander NS, et al. 
Lenalidomide plus high-dose dexamethasone versus 
lenalidomide plus low-dose dexamethasone as initial 
therapy for newly diagnosed multiple myeloma: an 
open-label randomized controlled trial. Lancet Oncol. 
2010;11(1):29–37.
[36] Hulin C, Belch A, Shutik C, et al. Updated outcomes 
and impact of age with lenalidomide and low-dose 
dexamethasone or melphalan, prednisone, and thali-
domide in the randomized, phase III FIRST trial. J Clin 
Oncol. 2016;34(30):3609–3617.
[37] Larocca A, Salvini M, Gaidano G, et al. Sparing steroids in 
elderly intermediate-fit newly diagnosed multiple mye-
loma patients treated with a dose/schedule-adjusted Rd 
vs. continuous Rd: results of RV-MM-PI-0752 phase III 
randomized study. EHA. 2019;166385:PF586.
[38] Facon T, Lee J, Moreau P, et al. Phase 3 study 
(CLARION) of carfilzomib, melphalan, prednisone 
(KMP) vs. bortezomib, melphalan, prednisone in 
newly diagnosed multiple myeloma (NDMM). Clin 
Lymph Myel Leuk. 2017;1:e26–e27.
[39] Reeder CB, Reece DE, Kukreti V, et al. Once- versus 
twice-weekly bortezomib induction therapy with 
CyBorD in newly diagnosed multiple myeloma. 
Blood. 2010;115(16):3416–3417.
[40] Mateos MV, Dimopoulos MA, Cavo M, et al. 
Daratumumab plus bortezomib, melphalan, and pre-
dnisone for untreated myeloma. N Engl J Med. 
2018;378(6):518–528.
[41] Mateos MV, Cavo M, Bladé J, et al. Daratumumab plus 
bortezomib, melphalan, and prednisone versus bortezo-
mib, melphalan, and prednisone in patients with 
transplant-ineligible newly diagnosed multiple myeloma: 
overall survival in Alcyone. Blood. 2019;134(suppl 1):859.
[42] Stege C, Nasserinejad K, van der Spek E, et al. Efficacy 
and tolerability of ixazomib, daratumumab and low 
dose dexamethasone (Ixa Dara dex) in unfit and frail 
newly diagnosed multiple myeloma (NDMM) patients: 
results of the interim analysis of the phase II HOVON 
143 study. Blood. 2019;134(suppl1:695.
[43] Facon T, Kumar S, Plesner T, et al. Daratumumab plus 
lenalidomide and dexamethasone for untreated 
myeloma. N Engl J Med. 2019;380(22):2104–2115.
[44] Facon T, Dimopoulos MA, Dispenzieri A, et al. Final 
analysis of survival outcomes in the phase 3 FIRST 
trial of up-front treatment for multiple myeloma. 
Blood. 2018;131(3):301–310.
[45] Moreau P, Hulin C, Macro M, et al. VTD is superior to 
VCD prior to intensive therapy in multiple myeloma: 
results of the prospective IFM2013-04 trial. Blood. 
2016;127(21):2569–2574.
14 M.-C. VEKEMANS ET AL.
[46] Attal M, Lauwers-Cances V, Hulin C, et al. 
Lenalidomide, bortezomib, and dexamethasone with 
transplantation for myeloma. N Engl J Med. 2017;376 
(14):1311–1320.
[47] Rosinol L, Oriol A, Rios R, et al. Bortezomib, lenalido-
mide, and dexamethasone as induction therapy prior 
to autologous transplant in multiple myeloma. Blood. 
2019;134(16):1337–1345.
[48] Gay F, Cerrato C, Petrucci MT, et al. Efficacy of carfilzo-
mib lenalidomide dexamethasone (KRd) with or with-
out transplantation in newly diagnosed myeloma 
according to risk status: results from the FORTE trial. 
J Clin Oncol. 2019;37(15suppl):8002.
[49] Moreau P, Attal M, Hulin C, et al. Bortezomib, thalido-
mide, and dexamethasone with or without daratumu-
mab before and after autologous stem-cell transplan 
tation for newly diagnosed multiple myeloma (CASSIO 
PEIA): a randomised, open-label, phase 3 study. 
Lancet. 2019;394(10192):29–38.
[50] Voorhees PM, Kaufman JL, Laubach JP, et al. Depth of 
response to daratumumab (DARA), lenalidomide, bor-
tezomib, and dexamethasone (RVd) improves over 
time in patients (pts) with transplant-eligible newly 
diagnosed multiple myeloma (NDMM): griffin study 
update. Blood. 2019;134(suppl 1):691.
[51] Costa LJ, Chhabra S, Godby KN, et al. Daratumumab, 
carfilzomib, lenalidomide and dexamethasone (Dara- 
KRd) induction, autologous transplantation and post- 
transplant, response-adapted, measurable residual 
disease (MRD)—based Dara-KRd consolidation in 
patients with newly diagnosed multiple myeloma 
(NDMM). Blood. 2019;134(suppl 1):860.
[52] Vij R, Kumar S, Zhang MJ, et al. Impact of pretransplant 
therapy and depth of disease response before auto-
logous transplantation for multiple myeloma. Biol 
Blood Marrow Transplant. 2015;21(2):335–341.
[53] Kumar S, Dispenzieri A, Lacy MQ, et al. Impact of 
lenalidomide therapy on stem cell mobilization and 
engraftment post-peripheral blood stem cell trans-
plantation in patients with newly diagnosed 
myeloma. Leukemia. 2007;21(9):2035–2542.
[54] Dimopoulos MA, Sonneveld P, Leung N, et al. 
International myeloma working group recommenda-
tions for the diagnosis and management of myeloma- 
related renal impairment. J Clin Oncol. 2016;34 
(13):1544–1557.
[55] Roussel M, Moreau P, Huynh A, et al. Bortezomib and 
high-dose melphalan as conditioning regimen before 
autologous stem cell transplantation in patients with 
de novo multiple myeloma: a phase 2 study of the 
intergroup francophone du myelome (IFM). Blood. 
2010;115(1):32–37.
[56] Cavo M, Gay F, Beksac M, et al. Autologous haemato-
poietic stem-cell transplantation versus bortezomib- 
melphalan-prednisone, with or without bortezomib- 
lenalidomide-dexamethasone consolidation therapy, 
and lenalidomide maintenance for newly diagnosed 
multiple myeloma (EMN02/HO95): a multicenter, ran-
domized, open-label, phase 3 study. Lancet Hematol. 
2020; DOI:10.1016/S2352-3026(20)30099-5
[57] Stadtmauer EA, Pasquini MC, Blackwell B, et al. 
Autologous transplantation, consolidation, and main-
tenance therapy in multiple myeloma: results of the 
BMT CTN 0702 trial. J Clin Oncol. 2019;37(7):589–597.
[58] Ladetto M, Pagliano G, Ferrero S, et al. Major tumor 
shrinking and persistent molecular remissions after 
consolidation with bortezomib, thalidomide, and 
dexamethasone in patients with autografted 
myeloma. J Clin Oncol. 2010;28(12):2077–2084.
[59] Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with 
thalidomide plus dexamethasone compared with tha-
lidomide plus dexamethasone as induction therapy 
before, and consolidation therapy after, double autol 
ogous stem-cell transplantation in newly diagnosed 
multiple myeloma: a randomised phase 3 study. 
Lancet. 2010;376(9758):2075–2085.
[60] McCarthy PL, Holstein SA, Petrucci MT, et al. 
Lenalidomide maintenance after autologous stem- 
cell transplantation in newly diagnosed multiple mye-
loma: A meta-analysis. J Clin Oncol. 2017;35(29):3279– 
3289.
[61] Jackson GH, Davies FE, Pawlyn C, et al. Lenalidomide 
maintenance versus observation for patients with 
newly diagnosed multiple myeloma (myeloma XI): 
a multicentre, open-label, randomised, phase 3 trial. 
Lancet Oncol. 2019;20(1):57–73.
[62] Sonneveld P, Schmidt-Wolf IG, van der Holt B, et al. 
Bortezomib induction and maintenance treatment 
in patients with newly diagnosed multiple mye-
loma: results of the randomized phase III HOVON 
65/GMMG-HD4 trial. J Clin Oncol. 2012;30 
(24):2946–2955.
[63] Dimopoulos MA, Gay F, Schjesvold F, et al. Oral ixazo-
mib maintenance following autologous stem cell 
transplantation (TOURMALINE-MM3): a double-blind, 
randomised, placebo-controlled phase 3 trial. Lancet. 
2019;393(10168):253–264.
[64] Knop S, Engelhardt M, Liebisch P, et al. Allogeneic 
transplantation in multiple myeloma: long-term 
follow-up and cytogenetic subgroup analysis. Leuke 
mia. 2019;33(11):2710–2719.
[65] Kumar S, Paiva B, Anderson KC, et al. International 
myeloma working group consensus criteria for respo 
nse and minimal residual disease assessment in multi-
ple myeloma. Lancet Oncol. 2016;17(8):e328–e346.
[66] Mohan M, Weinhold N, Schinke C, et al. Daratumumab 
in high-risk relapsed/refractory multiple myeloma 
patients: adverse effect of chromosome 1q21 gain/ 
amplification and GEP70 status on outcome. Br 
J Haematol. 2020;189(1):67–71.
[67] Michaelis LC, Saad A, Zhong X, et al. Salvage second 
hematopoietic cell transplantation in myeloma. Biol 
Blood Marrow Transplant. 2013;19(5):760–766.
[68] Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, 
lenalidomide, and dexamethasone for multiple 
myeloma. N Engl J Med. 2016;375(14):1319–1331.
[69] Siegel DS, Dimopoulos MA, Ludwig H, et al. Improvement 
in overall survival with carfilzomib, lenalidomide, and 
dexamethasone in patients with relapsed or refractory 
multiple myeloma. J Clin Oncol. 2018;36(8):728–734.
[70] Kastritis E, Roussou M, Gavriatopoulou M, et al. Impact 
on last lenalidomide dose, duration, and IMiD-free 
interval in patients with myeloma treated with poma 
lidomide/dexamethasone. Blood Adv. 2019;3(23):40 
95–4103.
[71] Richardson PG, Oriol A, Beksac M, et al. Pomalidomide, 
bortezomib, and dexamethasone for patients with 
relapsed or refractory multiple myeloma previously 
treated with lenalidomide (OPTIMISMM): a randomi 
sed, open-label, phase 3 trial. Lancet Oncol. 2019;20 
(6):781–794.
[72] Sonneveld P, Zweegman S, Cavo M, et al. Carfilzomib, 
pomalidomide and dexamethasone (KPd) in patients 
with multiple myeloma refractory to bortezomib and 
ACTA CLINICA BELGICA 15
lenalidomide, the EMN011 trial. Blood. 2018;132 
(suppl1):801.
[73] Dimopoulos MA, Palumbo A, Corradini P, et al. Safety 
and efficacy of pomalidomide plus low-dose dexa-
methasone in STRATUS (MM-010): a phase 3b study 
in refractory multiple myeloma. Blood. 2016;128 
(4):497–503.
[74] Baz RC, Martin TG, HY L, et al. Randomized multicenter 
phase 2 study of pomalidomide, cyclophosphamide, 
and dexamethasone in relapsed refractory myeloma. 
Blood. 2016;127(21):2561–2568.
[75] Dimopoulos MA, Dytfeld D, Grosicki S, et al. 
Elotuzumab plus pomalidomide and dexamethasone 
for multiple myeloma. N Engl J Med. 2018;379 
(19):1811–1822.
[76] Attal M, Richardson PG, Rajkumar SV, et al. Isatuximab 
plus pomalidomide and low-dose dexamethasone ver-
sus pomalidomide and low-dose dexamethasone in 
patients with relapsed and refractory multiple mye-
loma (ICARIA-MM): a randomised, multicentre, open- 
label, phase 3 study. Lancet. 2019;394(10214):2096– 
2107.
[77] Chari A, Suvannasankha A, Fay JW, et al. Daratumumab 
plus pomalidomide and dexamethasone in relapsed 
and/or refractory multiple myeloma. Blood. 2017;130 
(8):974–981.
[78] Usmani SZ, Weiss BM, Plesner T, et al. Clinical efficacy 
of daratumumab monotherapy in patients with heav-
ily pretreated relapsed or refractory multiple myeloma. 
Blood. 2016;128(1):37–44.
[79] Usmani A, Quach H, Mateos MV, et al. Carfilzomib, 
dexamethasone and daratumumab versus carfilzomib, 
dexamethasone for the treatment of patients with 
relapsed or refractory multiple myeloma (RRMM): pri-
mary analysis results from the randomised, open-label, 
phase 3 kandor (NCT03158688). Blood. 2019;134 
(suppl2):LBA–6.
[80] Gandhi UH, Cornell RF, Lakshman A, et al. Outcomes of 
patients with multiple myeloma refractory to CD-38 
targeted monoclonal antibody therapy. Leukemia. 
2019;33(9):2266–2275.
[81] Moreau P, Chanan-Khan A, Roberts AW, et al. 
Promising efficacy and acceptable safety of venetoclax 
plus bortezomib and dexamethasone in relapsed/ 
refractory MM. Blood. 2017;130(22):2392–2400.
[82] Kumar S, Harrison S, Cavo M, et al. A phase 3 study of 
venetoclax or placebo in combination with bortezo-
mib and dexamethasone in patients with relapsed/ 
refractory multiple myeloma. EHA. 2019;LB2601.
[83] Bahlis N, Sutherland H, White D, et al. Selinexor plus 
low-dose bortezomib and dexamethasone for patients 
with relapsed or refractory multiple myeloma. Blood. 
2018;132(24):2546–2554.
[84] Chari A, Vogl D, Gavriatopoulou M, et al. Oral 
selinexor-dexamethasone for triple-class refractory 
multiple myeloma. N Engl J Med. 2019;381(8):727–738.
[85] Richardson PG, Oriol A, Larocca A, et al. Horizon 
(OP-106) study of melflufen in patients relapsed/refrac-
tory multiple myeloma (RRMM) refractory to daratumu-
mab and/or pomalidomide: update efficacy and safety. 
Clin Lymph Myel Leuk. 2019;19(suppl1):S329–30.
[86] Ocio EM, Efebera YA, Granell M, et al. ANCHOR (OP- 
104): updated efficacy and safety from a phase ½ study 
of melflufen and dexamethasone plus bortezomib or 
daratumumab in patients with relapsed/refractory 
multiple myeloma (RRMM) refractory to an IMiD or 
a proteasome inhibitor (PI). Blood. 2019;134(suppl1: 
3124.
[87] Bjorklund CC, Kang J, Amatangelo M, et al. Iberdomide 
(CC-220) is a potent cereblon E3 ligase modulator with 
antitumor and immunostimulatory activities in 
lenalidomide- and pomalidomide-resistant multiple 
myeloma cells with dysregulated CRBN. Leukemia. 
2020;34(4):1197–1201.
[88] Lonial S, NWCJ VDD, Popat R, et al. First clinical (phase 
1b/2a) study of iberdomide (CC-220; IBER), a CELMoD, 
in combination with dexamethasone (DEX) in patients 
(pts) with relapsed/refractory multiple myeloma 
(RRMM). J Clin Oncol. 2020;37(15 suppl):8006.
[89] Trudel S, Lendvai N, Popat R, et al. Antibody-drug con-
jugate, GSK2857916, in relapsed/refractory multiple 
myeloma: an update on safety and efficacy from dose 
expansion phase I study. Blood Cancer J. 2019;9(4):37.
[90] Lonial S, Lee HC, Badros A, et al. Belantamab mafodo-
tin for relapsed or refractory multiple myeloma 
(DREAMM-2): a two-arm, randomized, open-label, 
phase 2 study. Lancet Oncol. 2019;21(2):207–221.
[91] Topp MS, Duell J, Zugmaier G, et al. Anti-B-cell matura-
tion antigen BiTE molecule AMG 420 induces 
responses in multiple myeloma. J Clin Oncol. 2020; 
JCO1902657. DOI:10.1200/JCO.19.02657
[92] Ali SA, Shi V, Maric I, et al. T cells expressing an 
anti-B-cell maturation antigen chimeric antigen recep-
tor cause remissions of multiple myeloma. Blood. 
2016;128(13):1688–1700.
[93] Brudno JN, Maric I, Hartman SD, et al. T Cells geneti-
cally modified to express an anti-B-cell maturation 
antigen chimeric antigen receptor cause remissions 
of poor-prognosis relapsed multiple myeloma. J Clin 
Oncol. 2018;36(22):2267–2280.
[94] Raje N, Berdeja J, Lin Y, et al. Anti-BCMA CAR T-cell 
therapy bb2121 in relapsed or refractory multiple 
myeloma. N Engl J Med. 2019;380(18):1726–1737.
[95] Cohen AD, Garfall AL, Stadtmauer EA, et al. B cell 
maturation antigen-specific CAR T cells are clinically 
active in multiple myeloma. J Clin Invest. 2019;129 
(6):2210–2221.
[96] Fernandez de Larrea C, RA K, BG D, et al. Plasma cell 
leukemia: consensus statement on diagnosis require-
ments, response criteria and treatment recommenda-
tions by the international myeloma working group. 
Leukemia. 2013;27(4):780–791.
[97] Granell M, Calvo X, Garcia-Guinon A, et al. Prognostic 
impact of circulating plasma cells in patients with multi-
ple myeloma: implications for plasma cell leukemia 
definition. Haematologica. 2017;102(6):1099–1104.
[98] Jurczyszyn A, Rodocha J, Davila J, et al. Prognostic 
indicators in primary plasma cell leukemia: 
a multicentre retrospective study of 117 patients. Br 
J Haematol. 2018;180(6):831–839.
[99] Royer B, Minvielle S, Diouf M, et al. Bortezomib, dox-
orubicin, cyclophosphamide, dexamethasone induc-
tion followed by stem cell transplantation for primary 
plasma cell leukemia: a prospective phase II study of 
the intergroup francophone du myélome. J Clin Oncol. 
2016;34(18):2125–2132.
[100] Nooka AK, Kaufman JL, Muppidi S, et al. Consolidation 
and maintenance therapy with lenalidomide, bortezo-
mib and dexamethasone (RVD) in high-risk myeloma 
patients. Leukemia. 2014;28(3):690–693.
[101] Gavriotopoulou M, Musto P, Caers J, et al. European 
myeloma network recommendations on diagnosis 
16 M.-C. VEKEMANS ET AL.
and management of patients with rare plasma cell 
dyscrasias. Leukemia. 2018;32(9):1883–1898.
[102] Jelinek T, Mihalyova J, Kascak M, et al. Single-agent 
venetoclax induces MRD-negative response in relap 
sed primary plasma cell leukemia with t(11;14). Am 
J Hematol. 2019;94(1):e35–e37.
[103] Sevcikova S, Minarik J, Stork M, et al. Extramedullary 
disease in multiple myeloma – controversies and 
future directions. Blood Rev. 2019;36:32–39.
[104] Moreau P, Zweegman S, Perrot A, et al. Evaluation of 
the prognostic value of positron emission tomogra 
phy-computed tomography (PET-CT) at diagnosis and 
follow-up in transplant-eligible newly diagnosed mul-
tiple myeloma (TE NDMM) patients treated in the 
phase 3 cassiopeia study: results of the cassiopet com-
panion study. Blood. 2019;134(suppl 1):692.
[105] Morgan GJ, Davies FE, Gregory WM, et al. First-line treat-
ment with zoledronic acid as compared with clodronic 
acid in multiple myeloma (MRC myeloma IX): a randomi 
sed controlled trial. Lancet. 2010;376(9757):744–751.
[106] Terpos E, Kleber M, Engelhardt M, et al. European 
myeloma network guidelines for the management of 
multiple myeloma-related complications. Haematolo 
gica. 2015;100(10):1254–1266.
[107] Raje N, Terpos E, Willenbacher W, et al. Denosumab 
versus zoledronic acid in bone disease treatment of 
newly diagnosed multiple myeloma: an international, 
double-blind, double-dummy, randomised, controlled, 
phase 3 study. Lancet Oncol. 2018;19(3):370–381.
[108] Terpos E, Morgan Mdel, Dimopoulos MA, et al. 
International working group recommendations for 
the treatment of multiple myeloma-related bone 
disease. J Clin Oncol. 2013;31(18):2347–2357.
[109] Chakraborty R, Majhail NS. Treatment and disease 
complications in multiple myeloma: implications for 
survivorship. Am J Hematol. 2020;95(6):672–690.
[110] Pegourie B, Karlin L, Benboubker L, et al. Apixaban for the 
prevention of thromboembolism in immunomodulatory- 
treated myeloma patients: myelaxat, a phase 2 pilot 
study. Am J Hematol. 2019;94(6):635–640.
[111] Storrar NPF, Mathur A, Johnson PRE, et al. Safety and 
efficacy of apixaban for routine thromboprophylaxis in 
myeloma patients treated with thalidomide- and 
lenalidomide- containing regimens. Br J Haematol. 
2019;185(1):142–144.
[112] Dumontet C, Hulin C, Dimopoulos MA, et al. 
A predictive model for risk of early grade ≥ 3 infections 
for patients with multiple myeloma not eligible for 
transplant: analysis of the FIRST trial. Leukemia. 
2018;32(6):1404–1413.
[113] Drayson MT, Bowcock S, Planche T, et al. Prophylactic 
levofloxacin to prevent infections in newly diagnosed 
symptomatic myeloma: the TEAMM RCT. Health 
Technol Assess. 2019;23(62):1–94.
[114] Wu Z, Mc Googan JM. Characteristics of and important 
lessons from the coronavirus disease 2019 (COVID-19) 
outbreak in China. JAMA. 2020;323(13):1239.
[115] tPalumbo A, Mina R. Management of older adults 
with multiple myeloma. Blood Rev. 2013;27 
(3):133–142.
[116] San Miguel JF, Schlag R, Khuageva NK, et al. Persistent 
overall survival benefit and no increased risk of second 
malignancies with bortezomib-melphalan-prednisone 
versus melphalan-prednisone in patients with pre-
viously untreated multiple myeloma. J Clin Oncol. 
2013;31(4):448–455.
[117] Bringhen S, Larocca A, Rossi D, et al. Efficacy and safety 
of once-weekly bortezomib in multiple myeloma 
patients. Blood. 2010;116(23):4745–4753.
[118] Moreau P, Avet-Loiseau H, Facon T, et al. Bortezomib 
plus dexamethasone versus reduced-dose bortezo 
mib, thalidomide plus dexamethasone as induction 
treatment before autologous stem cell transplantation 
in newly diagnosed multiple myeloma. Blood. 
2011;118(22):5752–5758.
[119] Dimopoulos MA, San-Miguel J, Belch A, et al. 
Daratumumab plus lenalidomide and dexamethasone 
versus lenalidomide and dexamethasone in relapsed 
or refractory multiple myeloma: updated analysis of 
POLLUX. Haematologica. 2018;103(12):2088–2096.
[120] Stewart AK, Rajkumar SV, Dimopoulos MA, et al. 
Carfilzomib, lenalidomide, and dexamethasone for 
relapsed multiple myeloma. N Engl J Med. 2015;372 
(2):142–152.
[121] Moreau P, Masszi T, Grzasko N, et al. Oral Ixazomib, 
lenalidomide, and dexamethasone for multiple 
myeloma. N Engl J Med. 2016;374(17):1621–1634.
[122] Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab 
therapy for relapsed or refractory multiple myeloma. 
N Engl J Med. 2015;373(7):621–631.
[123] Palumbo A, Chanan-Khan A, Weisel K, et al. 
Daratumumab, bortezomib, and dexamethasone for 
multiple myeloma. N Engl J Med. 2016;375(8):754–766.
[124] Spencer A, Lentzsch S, Weisel K, et al. Daratumumab 
plus bortezomib and dexamethasone versus bortezo-
mib and dexamethasone in relapsed or refractory mul-
tiple myeloma: updated analysis of CASTOR. 
Haematologica. 2018;103(12):2079–2087.
[125] San-Miguel JF, Hungria VT, Yoon SS, et al. 
Panobinostat plus bortezomib and dexamethasone 
versus placebo plus bortezomib and dexamethasone 
in patients with relapsed or relapsed and refractory 
multiple myeloma: a multicentre, randomised, 
double-blind phase 3 trial. Lancet Oncol. 2014;15 
(11):1195–1206.
[126] San-Miguel JF, Hungria VT, Yoon SS, et al. Overall 
survival of patients with relapsed multiple myeloma 
treated with panobinostat or placebo plus bortezomib 
and dexamethasone (the PANORAMA 1 trial): 
a randomised, placebo-controlled, phase 3 trial. 
Lancet Haematol. 2016;3(11):e506–e515.
[127] Moreau P, Dimopoulos MA, Mikhael J, et al. Isatuximab 
plus carfilzomib and dexamethasone vs carfilzomib 
and dexamethasone in relapsed/refractory multiple 
myeloma (IKEMA): interim analysis of a phase 3, ran-
domized, open-label study. EHA. 2020;LB2603.
[128] Dimopoulos MA, Moreau P, Palumbo A, et al. 
Carfilzomib and dexamethasone versus bortezomib 
and dexamethasone for patients with relapsed or 
refractory multiple myeloma (ENDEAVOR): a randomi 
sed, phase 3, open-label, multicentre study. Lancet 
Oncol. 2016;17(1):27–38.
[129] Dimopoulos MA, Goldschmidt H, Niesvizky R, et al. 
Carfilzomib or bortezomib in relapsed or refractory 
multiple myeloma (ENDEAVOR): an interim overall sur-
vival analysis of an open-label, randomised, phase 3 
trial. Lancet Oncol. 2017;18(10):1327–1337.
[130] Moreau P, Mateos MV, Berenson JR, et al. Once weekly 
versus twice weekly carfilzomib dosing in patients 
with relapsed and refractory multiple myeloma 
(ARROW): interim analysis results of a randomized, 
phase 3 study. Lancet Oncol. 2018;19(7):953–964.
ACTA CLINICA BELGICA 17
